Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The session is scheduled for September 16 at 8:30 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. For full details, see the press release.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. Its lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland.
This conference appearance matters for several reasons. First, it provides a platform for Helus Pharma to showcase its pipeline to a global audience of investors, healthcare executives, and analysts. With major depressive disorder and generalized anxiety disorder affecting millions worldwide, the company's progress with NSAs could signal a new treatment paradigm. The Breakthrough Therapy Designation for HLP003 underscores the FDA's recognition of its potential to offer substantial improvement over existing therapies. If successful, these treatments could provide durable improvements in mental health, reducing the burden on healthcare systems and improving patient outcomes.
Second, the event highlights the growing interest in psychedelic-inspired medicines. While Helus Pharma's NSAs are synthetic and not classic psychedelics, they target similar serotonin pathways. This approach may overcome some regulatory and logistical hurdles associated with traditional psychedelic therapies, which often require intensive monitoring. As a result, Helus Pharma's work could accelerate the mainstream adoption of serotonergic treatments in psychiatry.
Third, for investors, the fireside chat may offer insights into upcoming milestones, including Phase 3 data for HLP003 and Phase 2 results for HLP004. The company's newsroom at https://ibn.fm/HELP provides ongoing updates. Additionally, BioMedWire, a specialized communications platform, distributes news for the biotech sector, and more information is available at https://www.BioMedWire.com.
The broader impact extends to the mental health industry. If Helus Pharma's NSAs prove effective, they could reduce reliance on conventional antidepressants, which often take weeks to work and carry side effects. The company's focus on neuroplasticity suggests a potential for long-lasting benefits from short treatment courses. This could transform how depression and anxiety are managed, shifting from daily medication to targeted interventions. As the conference unfolds, industry leaders will be watching closely for signs of progress that could reshape psychiatric care.
